Clinical Trials during an infectious outbreaks: More questions than answers

Dr Arun Bhatt | Updated on May 08, 2020 Published on May 08, 2020

In epidemics, clinical trials usually include adult serious patients, who are hospitalised. The therapy has less chance of working in patients admitted late and suffering from serious irreversible organ damage   -  iStock

The world is facing a pandemic of COVID-19, for which there is no effective therapy. And any new therapy can be used in medical practice only if its efficacy is proved in clinical trials.

But the experience of previous outbreaks such as Ebola show that there are scientific and ethical challenges in planning clinical trials in patients with serious infections.

The first challenge is the choice of therapy. As there is no time for research and development of new drugs in a pandemic, so therapies already approved by health authorities, with known safety profile, are investigated. These could be tried, provided there is scientific evidence about their potential efficacy, based on biological mechanisms studied in laboratory or animal studies. However, approved standard doses of therapy may not be considered effective. If higher doses are to be investigated, there should be robust justification based on lab, animal, and human studies. But the risk of side effects would also be higher. And since there is a need for rapid action, health authorities and ethics committees expedite the approval process, with limited information available to evaluate the risk-benefit ratio of the investigational therapy.

The second challenge involves the selection of patients. In epidemics, clinical trials usually include adult serious patients who are hospitalized. The therapy has less of a chance of working in patients admitted late and suffering from serious irreversible organ damage. So, the physician should try to include patients suffering from a mild infection of short duration of illness. This would be practically demanding considering the delay in appearance of symptoms.

The third challenge is to do with the design of the clinical trial. For assessment of a new therapy, the best evidence comes from a Double Blind Randomized Controlled trial. Double blinding means that the participants and the physicians are not aware of which group of participants have been assigned to the active treatment or the inactive placebo. This reduces the risk of intentional or unintentional bias of patients and physicians, who are aware of which participants are getting which therapy.

High expectations from a new therapy could influence a patient’s reporting of clinical symptoms or the physician’s judgement in assessing subjective effects of the therapy. During an outbreak there is no time to manufacture good quality placebo. Hence, these would be open clinical trials, without blinding, comparing two groups: one that is given a combination of investigational therapy + standard care, and the other that group that’s given only standard care.

Randomization is a powerful method to reduce risk of bias in open trials. It means, each participant has an equal chance of being in any of the 2 groups. For the patients and family, randomization means accepting choice of receiving only standard care, when a potentially beneficial new therapy is available. For the physician, it would be unethical and impractical to ask the patients to consent to a randomized trial.

Informed consent, which is a patient’s voluntary agreement to participate in a clinical trial, requires an understanding of the relevant information. Seriously ill patients, who are vulnerable with impaired decision-making capacity, would not be able to make an informed decision. In addition to the challenges of language of consent and literacy level, the physician wearing full personal protective equipment would find communication with the patient difficult. Even the consent from family members may not be possible as they may be quarantined or hospitalized.

Due to such ethical challenges, most clinical trials in epidemics are open non-randomized single arm trials, where all patients receive the investigational therapy and standard care. Results of such trials provide early indication of activity but cannot be considered evidence of efficacy of the treatment. Additional well designed randomized blinded clinical trials would be necessary to establish efficacy of the investigational therapy for wider usage in population. As the severity of epidemic may diminish in few months, and number of patients decrease, planning another trial would be virtually impossible.

But the media’s interpretation of outcomes of an open clinical trial, and high societal pressure may influence health policy makers to support wide use of a still to be fully proved therapy. Which explains why planning a clinical trial during an infectious disease outbreak raises more questions, even as it offers few answers.

The writer is a consultant on clinical research and therapy development. Views are personal


Published on May 08, 2020

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!


Support Quality Journalism
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.